Are Polio Vaccines Increasing The Rate of Polio Paralysis?
This is an excerpt from:
Simian Virus 40 (SV40):
A Cancer Causing Monkey Virus from FDA-Approved Vaccines
The Creation and Production of the Polio Vaccines
In the 1950s, scientists like Doctors Jonas Salk and Albert Sabin had isolated the poliovirus strains to make vaccines. Dr. Salk’s strains would be inactivated with formaldehyde and injected into children. Dr. Sabin’s strains would be attenuated or weakened by transferring or passaging the live viruses through different host cells and then fed to children orally.
Because his goal was to create a live attenuated vaccine, Dr. Sabin had to isolate the poliovirus strains and then passage the strains through a myriad of host cells in order to attain the right virulence—strong enough to illicit an immune response, but weak enough so as to not cause polio in the recipient. Sabin’s oral polio vaccine (OPV) is a trivalent vaccine and was, therefore, comprised of three types - Type I, II, and III. For example, Type I has the following lineage: In 1941, Drs. Francis and Mack isolated the Mahoney poliovirus “from the pooled feces of three healthy children in Cleveland.”  Dr. Salk then subjected the strain to passages through fourteen living monkeys and two cultures of monkey testicular cultures. In 1954, the strain (now called Monk14 T2) was given to Drs. Li and Schaeffer who subjected the virus to nine more passages through monkey testicular cultures. Next, the strain (now called Monk14 T11) underwent fifteen more passages in monkey testicular cultures, eighteen passages in monkey kidney cells, two passages through the skin of living rhesus monkeys, and additional passages through African Green monkey skin and monkey kidney cell cultures. This strain was now called MS10 T43 or LS-c. In 1956, Dr. Sabin took this virus and passaged it through seven cultures of African Green Monkey kidney cells. That same year, the pharmaceutical company, Merck, Sharp & Dohme, passed the strain (now called LS-c, 2ab/KP2) through a rhesus monkey kidney cell culture. The resulting material was called Sabin Original Merck (SOM) and was provided to Lederle in 1960 as the seed material to manufacture its polio vaccine. Types II and III were created in a similar fashion.
Once their strains were isolated, pharmaceutical companies needed a method to propagate the viruses in order to produce the vast quantities of vaccine needed for nation-wide immunization campaigns. This required a substrate upon which the poliovirus could be efficiently grown and harvested. Kidney cells from rhesus monkeys were chosen because they were found to be an effective growth medium. A small quantity of poliovirus could be added to the minced kidneys surgically removed from these monkeys and within a few days, large quantities of poliovirus could then be harvested from these same monkey cells.
There was a problem, however, with using these monkey kidney cells to both create the original vaccine strains and grow the vaccine in large quantities. Monkeys contain simian viruses. When the poliovirus was passaged through the monkeys or grown on the monkey kidney cells for production, extraneous viruses became part of the final poliovirus vaccine. As early as 1953, Dr. Herald R. Cox, a scientist working at Lederle Laboratories, one of the polio vaccine manufacturers, published an article in a peer reviewed scientific journal in which he stated, “[P]oliomyelitis virus has so far been cultivated only in the tissues of certain susceptible species—namely, monkey or human tissues. Here again we would always be confronted with the potential danger of picking up other contaminating viruses or other microbic agents infectious for man.” In fact, in 1958, a scientific journal reported that “the rate of isolation of new simian viruses (from monkey kidney cells) has continued unabated.” Additionally, in 1960, the pharmaceutical company Merck & Co. wrote to the U.S. Surgeon General:
Our scientific staff have emphasized to us that there are a number of serious scientific and technical problems that must be solved before we could engage in large-scale production of live poliovirus vaccine. Most important among these is the problem of extraneous contaminating simian viruses that may be extremely difficult to eliminate and which may be difficult if not impossible to detect at the present stage of the technology.
The Discovery of Simian Virus 40 (SV40)
Between 1959 and 1960, Bernice Eddy, Ph.D., of the National Institute of Health (NIH) examined minced rhesus monkey kidney cells under a microscope. These were the cells of the same species of monkeys used to create and produce the oral polio vaccine. Dr. Eddy discovered that the cells would die without any apparent cause. She then took suspensions of the cellular material from these kidney cell cultures and injected them into hamsters. Cancers grew in the hamsters. Shortly thereafter, scientists at the pharmaceutical company Merck & Co. discovered what would later be determined to be the same virus identified by Eddy. This virus was named Simian Virus 40 or SV40 because it was the 40th simian virus found in monkey kidney cells.
In 1960, Doctors Benjamin Sweet and Maurice Hilleman, the Merck scientists who named the virus SV40, published their findings:
Viruses are commonly carried by monkeys and may appear as contaminants in cell cultures of their tissues, especially the kidney . . . . The discovery of this new virus, the vacuolating agent, represents the detection for the first time of a hitherto “non-detectable” simian virus of monkey renal cultures and raises the important question of the existence of other such viruses . . . . As shown in this report, all 3 types of Sabin’s live poliovirus vaccine, now fed to millions of persons of all ages, were contaminated with vacuolating virus.
The vacuolating virus was another name for SV40.
In 1962, Dr. Bernice Eddy published her findings in the journal produced by the Federation of American Societies for Experimental Biology. She wrote:
There is now an impressive list of oncogenic (cancer causing) viruses—the rabbit papilloma, polyoma, Rous sarcoma, the leukemia viruses . . . . It has been known for a number of years that monkeys harbor latent viruses . . . . The (SV40) virus was injected at once into 13 newborn hamsters and 10 newborn mice. Subcutaneous neoplasms indistinguishable from those induced by the rhesus monkey kidney extracts developed in 11 of the 13 hamsters between 156 and 380 days . . . .
Subsequent studies performed in the early 1960s demonstrated that SV40 caused brain tumors in animals and that SV40 could transform or turn cancerous normal human tissue in vitro. A disturbing experiment performed during this era also suggested that SV40 could cause human cancers in man in vivo. In 1964, Fred Jensen and his colleagues took tissue from patients who were terminally ill with cancer. They exposed the tissue to SV40 and then after it was transformed, they implanted the tissue back into the patient. These implants grew into tumors in their human hosts. This suggested the possibility that SV40 could cause cancers in man.